Detection and Pathogenesis of Novel Protein F

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04338386

Enrollment

100

Registered

2020-04-08

Start date

2020-04-15

Completion date

2028-03-14

Last updated

2020-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Disease, Multiple Myeloma

Keywords

diagnosis, protein, cardiac disease, multiple myeloma, globulin

Brief summary

From December 6, 2019 to March 23, 2020, the research group of Qingkun Fan found a novel protein(temporarily named protein F) in heparin anticoagulant plasma of three patients with heart disease. One patient was diagnosed with multiple myeloma.However, protein F cannot be detected by serum protein electrophoresis. Preliminary studies have shown that this novel protein F have an obvious absorption peak at about 600nm. Placed at 2-8 degrees for 7 days, protein F will be isolated from heparin plasma. To the naked eye, protein F appear to be transparent jelly between the red blood cells and the plasma. The specific protein F, how it is produced, how it causes disease are still unknown. This study will explore how to detect protein F and how it is produced.

Detailed description

Protein F screening was performed on anticoagulant blood plasma with heparin Lithium or blood serum by in-house turbidimetric method in Automatic biochemical analyzer. All patients were followed-up for 3 years by telephones, routine appointment out-patient clinic or returning visit.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* Testing total protein and albumin * Testing routine blood test

Exclusion criteria

* high triglycerides (TG\>5.00 mmol/L) * hyperbilirubinemia (TBIL\>170 mmol/L) * fat emulsion used in past 3 days * patients with hemolytic disease * pregnant and lactating women

Design outcomes

Primary

Measure	Time frame	Description
Concentration of plasma protein F content	six month	the protein F content was measured by turbidimetric assay in automatic biochemical analyzer

Secondary

Measure	Time frame	Description
Number of Participants with Multiple myeloma	3 years	Develop or be diagnosed with multiple myeloma

Contacts

Primary ContactQingkun Fan, MD

fqk@wahh.com.cn027-65796747

Outcome results